Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL)
    2.
    发明申请
    Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) 有权
    慢性淋巴细胞性白血病(CLL)的诊断与治疗

    公开(公告)号:US20090131353A1

    公开(公告)日:2009-05-21

    申请号:US12096628

    申请日:2006-12-07

    CPC分类号: C12Q1/6886 C12Q2600/158

    摘要: The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.

    摘要翻译: 本发明通过确定与CLL特别是PDE7B和/或PDE3B相关的环核苷酸磷酸二酯酶(PDE)的同种型的表达水平,以及PDE7B的mRNA表达比例与PDE7B的mRNA表达的比例,提供了用于诊断慢性淋巴细胞性白血病(CLL)的诊断方法和试剂盒 PDE3B。 本发明提供了CLL淋巴细胞相对于正常淋巴细胞均匀表达高水平的PDE7B和低水平的PDE3B。 还提供了一种治疗方法和用于CLL的药物组合物,其包含一种或多种能够调节与CLL相关的PDE的同种型的表达或活性水平和/或逆转PDE7B / PDE3B mRNA表达水平的比例的治疗剂。

    Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL)
    3.
    发明申请
    Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) 有权
    慢性淋巴细胞性白血病(CLL)的诊断与治疗

    公开(公告)号:US20110117562A1

    公开(公告)日:2011-05-19

    申请号:US12960955

    申请日:2010-12-06

    IPC分类号: C12Q1/44 C12Q1/68

    CPC分类号: C12Q1/6886 C12Q2600/158

    摘要: The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL, particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.

    摘要翻译: 本发明通过测定与CLL,特别是PDE7B和/或PDE3B相关的环状核苷酸磷酸二酯酶(PDEs)的同种型的表达水平以及PDE7B的mRNA表达的比例来提供用于诊断慢性淋巴细胞性白血病(CLL)的诊断方法和试剂盒 到PDE3B。 本发明提供了CLL淋巴细胞相对于正常淋巴细胞均匀表达高水平的PDE7B和低水平的PDE3B。 还提供了一种治疗方法和用于CLL的药物组合物,其包含一种或多种能够调节与CLL相关的PDE的同种型的表达或活性水平和/或逆转PDE7B / PDE3B mRNA表达水平的比例的治疗剂。

    Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
    4.
    发明授权
    Diagnosis and treatment of chronic lymphocytic leukemia (CLL) 有权
    慢性淋巴细胞性白血病(CLL)的诊断和治疗

    公开(公告)号:US08114590B2

    公开(公告)日:2012-02-14

    申请号:US12960955

    申请日:2010-12-06

    IPC分类号: C12Q1/68 C07H21/04

    CPC分类号: C12Q1/6886 C12Q2600/158

    摘要: The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL, particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.

    摘要翻译: 本发明通过测定与CLL,特别是PDE7B和/或PDE3B相关的环状核苷酸磷酸二酯酶(PDEs)的同种型的表达水平以及PDE7B的mRNA表达的比例来提供用于诊断慢性淋巴细胞性白血病(CLL)的诊断方法和试剂盒 到PDE3B。 本发明提供了CLL淋巴细胞相对于正常淋巴细胞均匀表达高水平的PDE7B和低水平的PDE3B。 还提供了一种治疗方法和用于CLL的药物组合物,其包含一种或多种能够调节与CLL相关的PDE的同种型的表达或活性水平和/或逆转PDE7B / PDE3B mRNA表达水平的比例的治疗剂。

    Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
    5.
    发明授权
    Diagnosis and treatment of chronic lymphocytic leukemia (CLL) 有权
    慢性淋巴细胞性白血病(CLL)的诊断和治疗

    公开(公告)号:US07846664B2

    公开(公告)日:2010-12-07

    申请号:US12096628

    申请日:2006-12-07

    IPC分类号: C12Q1/68 C07H21/02 C07H21/04

    CPC分类号: C12Q1/6886 C12Q2600/158

    摘要: The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.

    摘要翻译: 本发明通过确定与CLL特别是PDE7B和/或PDE3B相关的环核苷酸磷酸二酯酶(PDE)的同种型的表达水平,以及PDE7B的mRNA表达比例与PDE7B的mRNA表达的比例,提供了用于诊断慢性淋巴细胞性白血病(CLL)的诊断方法和试剂盒 PDE3B。 本发明提供了CLL淋巴细胞相对于正常淋巴细胞均匀表达高水平的PDE7B和低水平的PDE3B。 还提供了一种治疗方法和用于CLL的药物组合物,其包含一种或多种能够调节与CLL相关的PDE的同种型的表达或活性水平和/或逆转PDE7B / PDE3B mRNA表达水平的比例的治疗剂。

    PROGNOSTIC MARKERS IN CHRONIC LYMPHOCYTIC LEUKEMIA
    6.
    发明申请
    PROGNOSTIC MARKERS IN CHRONIC LYMPHOCYTIC LEUKEMIA 审中-公开
    慢性淋巴细胞白血病中的预后标记

    公开(公告)号:US20070243561A1

    公开(公告)日:2007-10-18

    申请号:US11675958

    申请日:2007-02-16

    IPC分类号: G01N33/53

    CPC分类号: G01N33/57426

    摘要: Methods and compositions for detecting a form of chronic lymphocytic leukemia in a subject are described which allow for distinguishing more aggressive forms of the disease from less aggressive forms. Particularly described methods include assaying a sample obtained from the subject having or suspected of having chronic lymphocytic leukemia for a marker selected from a vimentin cleavage product, annexin 5 and 6-phosphogluconolactonase. A combination of any of these markers may be assayed in particular embodiments of a method according to the present invention. In particular embodiments, detection of an intermediate weight vimentin cleavage product is indicative of a less aggressive form of CLL associated with good prognosis.

    摘要翻译: 描述了用于检测受试者中慢性淋巴细胞性白血病形式的方法和组合物,其允许将更具侵略性的形式的疾病与较不具侵略性的形式区分开。 特别描述的方法包括测定从具有或疑似具有慢性淋巴细胞性白血病的受试者获得的样品用于选自波形蛋白裂解产物,膜联蛋白5和6-磷酸葡萄糖聚糖内切酶的标记。 任何这些标记物的组合可以在根据本发明的方法的具体实施方案中进行测定。 在具体实施方案中,中等重量波形蛋白切割产物的检测指示与良好预后相关的较低侵袭性的CLL形式。